Daxor (DXR)
(Delayed Data from NSDQ)
$9.00 USD
+0.30 (3.45%)
Updated Aug 15, 2024 09:55 AM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
DXR 9.00 +0.30(3.45%)
Will DXR be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for DXR based on the 1-3 month trading system that more than doubles the S&P 500.
Other News for DXR
Daxor Corporation Awarded $1.9M Contract by The U.S. Air Force for Development of its Next Generation Tracer System in its Point-of-Care Blood Volume Analyzer
Daxor awarded $1.9M contract by the U.S. Air Force
Daxor Expands To Three New Facilities As Blood Volume Analysis Technology Gains Momentum Nationwide
Daxor expands blood volume analysis in three new facilities
Daxor awarded $550K matching-fund extension from U.S. DHA